These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. NF-kappaB and IKK as therapeutic targets in cancer. Kim HJ; Hawke N; Baldwin AS Cell Death Differ; 2006 May; 13(5):738-47. PubMed ID: 16485028 [TBL] [Abstract][Full Text] [Related]
3. Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies. Panwalkar A; Verstovsek S; Giles F Cancer; 2004 Apr; 100(8):1578-89. PubMed ID: 15073843 [TBL] [Abstract][Full Text] [Related]
4. Regulation and function of IKK and IKK-related kinases. Häcker H; Karin M Sci STKE; 2006 Oct; 2006(357):re13. PubMed ID: 17047224 [TBL] [Abstract][Full Text] [Related]
5. NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. Breccia M; Alimena G Expert Opin Ther Targets; 2010 Nov; 14(11):1157-76. PubMed ID: 20858024 [TBL] [Abstract][Full Text] [Related]
6. The NF-kappaB transcription factor pathway as a therapeutic target in cancer: methods for detection of NF-kappaB activity. Mauro C; Zazzeroni F; Papa S; Bubici C; Franzoso G Methods Mol Biol; 2009; 512():169-207. PubMed ID: 19347278 [TBL] [Abstract][Full Text] [Related]
7. NF-kappaB in cancer--a friend turned foe. Ravi R; Bedi A Drug Resist Updat; 2004 Feb; 7(1):53-67. PubMed ID: 15072771 [TBL] [Abstract][Full Text] [Related]
8. NF-kappaB as a therapeutic target in chronic lymphocytic leukemia. Lopez-Guerra M; Colomer D Expert Opin Ther Targets; 2010 Mar; 14(3):275-88. PubMed ID: 20148715 [TBL] [Abstract][Full Text] [Related]
9. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Van Waes C Clin Cancer Res; 2007 Feb; 13(4):1076-82. PubMed ID: 17317814 [TBL] [Abstract][Full Text] [Related]
15. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells. Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088 [TBL] [Abstract][Full Text] [Related]
16. Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies. Fuchs O Curr Mol Pharmacol; 2010 Nov; 3(3):98-122. PubMed ID: 20594187 [TBL] [Abstract][Full Text] [Related]
17. IkappaB kinase beta (IKKbeta/IKK2/IKBKB)--a key molecule in signaling to the transcription factor NF-kappaB. Schmid JA; Birbach A Cytokine Growth Factor Rev; 2008 Apr; 19(2):157-65. PubMed ID: 18308615 [TBL] [Abstract][Full Text] [Related]
18. Nuclear factor-kappaB activation: from bench to bedside. Sethi G; Sung B; Aggarwal BB Exp Biol Med (Maywood); 2008 Jan; 233(1):21-31. PubMed ID: 18156302 [TBL] [Abstract][Full Text] [Related]
19. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462 [TBL] [Abstract][Full Text] [Related]